Unbound (bioavailable) IGF1 enhances somatic growth

Sebastien Elis, Yingjie Wu, Hayden William Courtland, Dara Cannata, Hui Sun, Mordechay Beth-On, Chengyu Liu, Hector Jasper, Horacio Domené, Liliana Karabatas, Clara Guida, Jelena Basta-Pljakic, Luis Cardoso, Clifford J. Rosen, Jan Frystyk, Shoshana Yakar

Research output: Contribution to journalArticle

Abstract

Understanding insulin-like growth factor-1 (IGF1) biology is of particular importance because, apart from its role in mediating growth, it plays key roles in cellular transformation, organ regeneration, immune function, development of the musculoskeletal system and aging. IGF1 bioactivity is modulated by its binding to IGF-binding proteins (IGFBPs) and the acid labile subunit (ALS), which are present in serum and tissues. To determine whether IGF1 binding to IGFBPs is necessary to facilitate normal growth and development, we used a gene-targeting approach and generated two novel knock-in mouse models of mutated IGF1, in which the native Igf1 gene was replaced by Des-Igf1 (KID mice) or R3-Igf1 (KIR mice). The KID and KIR mutant proteins have reduced affinity for the IGFBPs, and therefore present as unbound IGF1, or 'free IGF1'. We found that both KID and KIR mice have reduced serum IGF1 levels and a concomitant increase in serum growth hormone levels. Ternary complex formation of IGF1 with the IGFBPs and the ALS was markedly reduced in sera from KID and KIR mice compared with wild type. Both mutant mice showed increased body weight, body and bone lengths, and relative lean mass. We found selective organomegaly of the spleen, kidneys and uterus, enhanced mammary gland complexity, and increased skeletal acquisition. The KID and KIR models show unequivocally that IGF1-complex formation with the IGFBPs is fundamental for establishing normal body and organ size, and that uncontrolled IGF bioactivity could lead to pathological conditions.

Original languageEnglish (US)
Pages (from-to)649-658
Number of pages10
JournalDMM Disease Models and Mechanisms
Volume4
Issue number5
DOIs
StatePublished - Sep 2011

Fingerprint

Somatomedins
Insulin-Like Growth Factor Binding Proteins
Growth
Bioactivity
Serum
Musculoskeletal Development
Genes
Musculoskeletal system
Insulin-Like Growth Factor Binding Protein 1
Acids
Organ Size
Gene Targeting
Body Size
Mutant Proteins
Human Mammary Glands
Growth and Development
Growth Hormone
Uterus
Regeneration
Bone

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)

Cite this

Elis, S., Wu, Y., Courtland, H. W., Cannata, D., Sun, H., Beth-On, M., ... Yakar, S. (2011). Unbound (bioavailable) IGF1 enhances somatic growth. DMM Disease Models and Mechanisms, 4(5), 649-658. https://doi.org/10.1242/dmm.006775

Unbound (bioavailable) IGF1 enhances somatic growth. / Elis, Sebastien; Wu, Yingjie; Courtland, Hayden William; Cannata, Dara; Sun, Hui; Beth-On, Mordechay; Liu, Chengyu; Jasper, Hector; Domené, Horacio; Karabatas, Liliana; Guida, Clara; Basta-Pljakic, Jelena; Cardoso, Luis; Rosen, Clifford J.; Frystyk, Jan; Yakar, Shoshana.

In: DMM Disease Models and Mechanisms, Vol. 4, No. 5, 09.2011, p. 649-658.

Research output: Contribution to journalArticle

Elis, S, Wu, Y, Courtland, HW, Cannata, D, Sun, H, Beth-On, M, Liu, C, Jasper, H, Domené, H, Karabatas, L, Guida, C, Basta-Pljakic, J, Cardoso, L, Rosen, CJ, Frystyk, J & Yakar, S 2011, 'Unbound (bioavailable) IGF1 enhances somatic growth', DMM Disease Models and Mechanisms, vol. 4, no. 5, pp. 649-658. https://doi.org/10.1242/dmm.006775
Elis S, Wu Y, Courtland HW, Cannata D, Sun H, Beth-On M et al. Unbound (bioavailable) IGF1 enhances somatic growth. DMM Disease Models and Mechanisms. 2011 Sep;4(5):649-658. https://doi.org/10.1242/dmm.006775
Elis, Sebastien ; Wu, Yingjie ; Courtland, Hayden William ; Cannata, Dara ; Sun, Hui ; Beth-On, Mordechay ; Liu, Chengyu ; Jasper, Hector ; Domené, Horacio ; Karabatas, Liliana ; Guida, Clara ; Basta-Pljakic, Jelena ; Cardoso, Luis ; Rosen, Clifford J. ; Frystyk, Jan ; Yakar, Shoshana. / Unbound (bioavailable) IGF1 enhances somatic growth. In: DMM Disease Models and Mechanisms. 2011 ; Vol. 4, No. 5. pp. 649-658.
@article{1f7ec4f3590b441cb2798259139e56f9,
title = "Unbound (bioavailable) IGF1 enhances somatic growth",
abstract = "Understanding insulin-like growth factor-1 (IGF1) biology is of particular importance because, apart from its role in mediating growth, it plays key roles in cellular transformation, organ regeneration, immune function, development of the musculoskeletal system and aging. IGF1 bioactivity is modulated by its binding to IGF-binding proteins (IGFBPs) and the acid labile subunit (ALS), which are present in serum and tissues. To determine whether IGF1 binding to IGFBPs is necessary to facilitate normal growth and development, we used a gene-targeting approach and generated two novel knock-in mouse models of mutated IGF1, in which the native Igf1 gene was replaced by Des-Igf1 (KID mice) or R3-Igf1 (KIR mice). The KID and KIR mutant proteins have reduced affinity for the IGFBPs, and therefore present as unbound IGF1, or 'free IGF1'. We found that both KID and KIR mice have reduced serum IGF1 levels and a concomitant increase in serum growth hormone levels. Ternary complex formation of IGF1 with the IGFBPs and the ALS was markedly reduced in sera from KID and KIR mice compared with wild type. Both mutant mice showed increased body weight, body and bone lengths, and relative lean mass. We found selective organomegaly of the spleen, kidneys and uterus, enhanced mammary gland complexity, and increased skeletal acquisition. The KID and KIR models show unequivocally that IGF1-complex formation with the IGFBPs is fundamental for establishing normal body and organ size, and that uncontrolled IGF bioactivity could lead to pathological conditions.",
author = "Sebastien Elis and Yingjie Wu and Courtland, {Hayden William} and Dara Cannata and Hui Sun and Mordechay Beth-On and Chengyu Liu and Hector Jasper and Horacio Domen{\'e} and Liliana Karabatas and Clara Guida and Jelena Basta-Pljakic and Luis Cardoso and Rosen, {Clifford J.} and Jan Frystyk and Shoshana Yakar",
year = "2011",
month = "9",
doi = "10.1242/dmm.006775",
language = "English (US)",
volume = "4",
pages = "649--658",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "5",

}

TY - JOUR

T1 - Unbound (bioavailable) IGF1 enhances somatic growth

AU - Elis, Sebastien

AU - Wu, Yingjie

AU - Courtland, Hayden William

AU - Cannata, Dara

AU - Sun, Hui

AU - Beth-On, Mordechay

AU - Liu, Chengyu

AU - Jasper, Hector

AU - Domené, Horacio

AU - Karabatas, Liliana

AU - Guida, Clara

AU - Basta-Pljakic, Jelena

AU - Cardoso, Luis

AU - Rosen, Clifford J.

AU - Frystyk, Jan

AU - Yakar, Shoshana

PY - 2011/9

Y1 - 2011/9

N2 - Understanding insulin-like growth factor-1 (IGF1) biology is of particular importance because, apart from its role in mediating growth, it plays key roles in cellular transformation, organ regeneration, immune function, development of the musculoskeletal system and aging. IGF1 bioactivity is modulated by its binding to IGF-binding proteins (IGFBPs) and the acid labile subunit (ALS), which are present in serum and tissues. To determine whether IGF1 binding to IGFBPs is necessary to facilitate normal growth and development, we used a gene-targeting approach and generated two novel knock-in mouse models of mutated IGF1, in which the native Igf1 gene was replaced by Des-Igf1 (KID mice) or R3-Igf1 (KIR mice). The KID and KIR mutant proteins have reduced affinity for the IGFBPs, and therefore present as unbound IGF1, or 'free IGF1'. We found that both KID and KIR mice have reduced serum IGF1 levels and a concomitant increase in serum growth hormone levels. Ternary complex formation of IGF1 with the IGFBPs and the ALS was markedly reduced in sera from KID and KIR mice compared with wild type. Both mutant mice showed increased body weight, body and bone lengths, and relative lean mass. We found selective organomegaly of the spleen, kidneys and uterus, enhanced mammary gland complexity, and increased skeletal acquisition. The KID and KIR models show unequivocally that IGF1-complex formation with the IGFBPs is fundamental for establishing normal body and organ size, and that uncontrolled IGF bioactivity could lead to pathological conditions.

AB - Understanding insulin-like growth factor-1 (IGF1) biology is of particular importance because, apart from its role in mediating growth, it plays key roles in cellular transformation, organ regeneration, immune function, development of the musculoskeletal system and aging. IGF1 bioactivity is modulated by its binding to IGF-binding proteins (IGFBPs) and the acid labile subunit (ALS), which are present in serum and tissues. To determine whether IGF1 binding to IGFBPs is necessary to facilitate normal growth and development, we used a gene-targeting approach and generated two novel knock-in mouse models of mutated IGF1, in which the native Igf1 gene was replaced by Des-Igf1 (KID mice) or R3-Igf1 (KIR mice). The KID and KIR mutant proteins have reduced affinity for the IGFBPs, and therefore present as unbound IGF1, or 'free IGF1'. We found that both KID and KIR mice have reduced serum IGF1 levels and a concomitant increase in serum growth hormone levels. Ternary complex formation of IGF1 with the IGFBPs and the ALS was markedly reduced in sera from KID and KIR mice compared with wild type. Both mutant mice showed increased body weight, body and bone lengths, and relative lean mass. We found selective organomegaly of the spleen, kidneys and uterus, enhanced mammary gland complexity, and increased skeletal acquisition. The KID and KIR models show unequivocally that IGF1-complex formation with the IGFBPs is fundamental for establishing normal body and organ size, and that uncontrolled IGF bioactivity could lead to pathological conditions.

UR - http://www.scopus.com/inward/record.url?scp=80052281596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052281596&partnerID=8YFLogxK

U2 - 10.1242/dmm.006775

DO - 10.1242/dmm.006775

M3 - Article

C2 - 21628395

AN - SCOPUS:80052281596

VL - 4

SP - 649

EP - 658

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 5

ER -